A QUADRUPLE IMMUNOSUPPRESSIVE REGIMEN WHICH INCLUDES BASILIXIMAB INDUCTION WITH EARLY, C2-MONITORED NEORAL® CAN PROVIDE GOOD EFFICACY AND TOLERABILITY: RESULTS OF A 6-MONTH, MULTICENTER, U.S. TRIAL IN DE NOVO RENAL TRANSPLANTATION.

2004 ◽  
Vol 78 ◽  
pp. 454
Author(s):  
F Vincenti ◽  
Ralph Barbato
Keyword(s):  
Renal Transplantation ◽  
De Novo ◽  
Immunosuppressive Regimen ◽  
Good Efficacy

scholarly journals Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study

2010 ◽  
Vol 10 (12) ◽  
pp. 2632-2643 ◽  
Author(s):  
B. K. Krämer ◽  
B. Charpentier ◽  
L. Bäckman ◽  
H. Tedesco Silva Jr ◽  
G. Mondragon-Ramirez ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
De Novo ◽  
Phase Iii ◽  
Once Daily ◽  
Phase Iii Study

scholarly journals FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study

2011 ◽  
Vol 26 (11) ◽  
pp. 3802-3805 ◽  
Author(s):  
Andries J. Hoitsma ◽  
Ervin S. Woodle ◽  
Daniel Abramowicz ◽  
Pieter Proot ◽  
Yves Vanrenterghem
Keyword(s):  
Renal Transplantation ◽  
De Novo ◽  
Randomized Study ◽  
Open Label

scholarly journals Protocol Biopsies on de novo Renal-Transplants at 3 Months after Surgery: Impact on 5-Year Transplant Survival

2021 ◽  
Vol 10 (16) ◽  
pp. 3635
Author(s):  
Florian Terrec ◽  
Johan Noble ◽  
Hamza Naciri-Bennani ◽  
Paolo Malvezzi ◽  
Bénédicte Janbon ◽  
...  
Keyword(s):  
Graft Survival ◽  
Kidney Biopsy ◽  
De Novo ◽  
Immunosuppressive Regimen ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Post Transplantation ◽  
Kaplan Meier ◽  
Single Center Study ◽  
Protocol Biopsies

Background: In many centers, a protocol kidney biopsy (PKB) is performed at 3 months post-transplantation (M3), without a demonstrated benefit on death-censored graft survival (DCGS). In this study, we compared DCGS between kidney transplant recipients undergoing a PKB or without such biopsy while accounting for the obvious indication bias. Methods: In this retrospective, single-center study conducted between 2007 and 2013, we compared DCGS with respect to the availability and features of a PKB. We built a propensity score (PS) to account for PKB indication likelihood and adjusted the DCGS analysis on PKB availability and the PS. Results: A total of 615 patients were included: 333 had a PKB, 282 did not. In bivariate Kaplan–Meier survival analysis, adjusting for the availability of a PKB and for the PS, a PKB was associated with a better 5-year DCGS independently of the PS (p < 0.001). Among the PKB+ patients, 87 recipients (26%) had IF/TA > 0. Patients with an IF/TA score of 3 had the worst survival. A total of 144 patients (44%) showed cv lesions. Patients with cv2 and cv3 lesions had the worst 5-year DCGS. Conclusions: A M3 PKB was associated with improved graft survival independently of potential confounders. These results could be explained by the early treatment of subclinical immunological events. It could be due to better management of the immunosuppressive regimen.

CNI SPARING WITH MYCOPHENOLATE MOFETIL IN DE NOVO RENAL TRANSPLANTATION: 3-YEAR RESULTS FROM THE SYMPHONY STUDY

2008 ◽  
Vol 86 (Supplement) ◽  
pp. 218-219 ◽  
Author(s):  
H Ekberg ◽  
H Tedesco-Silva ◽  
A Demirbas ◽  
S Vitko ◽  
J Klempnauer ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
De Novo

scholarly journals Clinical Presentation, Outcomes, and Treatment of Membranous Nephropathy after Transplantation

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Artur Q. B. da Silva ◽  
Taina V. de Sandes-Freitas ◽  
Juliana B. Mansur ◽  
Jose Osmar Medicina-Pestana ◽  
Gianna Mastroianni-Kirsztajn
Keyword(s):  
Membranous Nephropathy ◽  
Clinical Presentation ◽  
Patient Survival ◽  
De Novo ◽  
Immunosuppressive Regimen ◽  
Graft Dysfunction ◽  
Class V ◽  
Clinical Presentations ◽  
Number Of Patients ◽  
Standard Strategy

There are scarce data about clinical presentation and outcomes of posttransplant membranous nephropathy (MN), and few reports include a large number of patients. This was a retrospective cohort including adult patients with posttransplant MN transplanted between 1983 and 2015 in a single center (n=41). Only patients with histological diagnosis of MN in kidney grafts were included. Clinical and laboratory presentation, histological findings, treatment, and outcomes were detailed. Patients were predominantly male (58.5%), with a mean age of 49.4 ± 13.2 years; 15 were considered as recurrent primary MN; 3 were class V lupus nephritis; 14 were considered as de novo cases, 7 secondary and 7 primary MN; and 9 cases were considered primary but it was not possible to distinguish between de novo MN and recurrence. Main clinical presentations were proteinuria (75.6%) and graft dysfunction (34.1%). Most patients with primary recurrent and de novo primary MN were submitted to changes in maintenance immunosuppressive regimen, but no standard strategy was identified; 31 patients presented partial or complete remission, and glomerulopathy appeared not to impact graft and patient survival.

FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia

2006 ◽  
Vol 6 (12) ◽  
pp. 2912-2921 ◽  
Author(s):  
M. Salvadori ◽  
K. Budde ◽  
B. Charpentier ◽  
J. Klempnauer ◽  
B. Nashan ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Renal Transplantation ◽  
De Novo ◽  
Controlled Trial ◽  
Randomized Controlled

TARGETING UPPER EVEROLIMUS BLOOD LEVELS WITH VERY LOW-DOSE CYCLOSPORINE IS EFFECTIVE AND SAFE IN DE NOVO RENAL TRANSPLANTATION

2008 ◽  
Vol 86 (Supplement) ◽  
pp. 158 ◽  
Author(s):  
M Salvadori ◽  
M Scolari ◽  
E Bertoni ◽  
F Citterio ◽  
P Rigotti ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Low Dose ◽  
De Novo ◽  
Blood Levels
Sign in / Sign up

Export Citation Format

Share Document